Nissim Sasson

Rehovot, M, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis.

Journal: Muscle & nerve

Published: May 02, 2025

Analysis of Long-Term Function and Survival of Edaravone Oral Suspension-Treated Patients With Amyotrophic Lateral Sclerosis Using PRO-ACT Data as Historical Placebo Controls.

Analysis of Long-Term Function and Survival of Edaravone Oral Suspension-Treated Patients With Amyotrophic Lateral Sclerosis Using PRO-ACT Data as Historical Placebo Controls.

Journal: Muscle & nerve

Published: October 31, 2024

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02).

Journal: Muscle & nerve

Published: October 23, 2024

Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment.

Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment.

Journal: Muscle & nerve

Published: October 17, 2024

Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study.

Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study.

Journal: Parkinsonism & related disorders

Published: September 26, 2024

Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.

Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.

Journal: The Lancet. Neurology

Published: November 16, 2023

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 11, 2021

ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.

ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.

Journal: Parkinsonism & related disorders

Published: July 29, 2021

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: April 18, 2021

Demonstration of a Speckle Based Sensing with Pulse-Doppler Radar for Vibration Detection.

Demonstration of a Speckle Based Sensing with Pulse-Doppler Radar for Vibration Detection.

Journal: Sensors (Basel, Switzerland)

Published: March 12, 2018

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Journal: International journal of MS care

Published: March 01, 2017

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.

Journal: BMC neurology

Published: January 26, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026